Posts by: Patricia Inacio PhD

Patricia Inacio PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

October 15, 2020October 15, 2020

HSCT of Greater Benefit to Children with Confirmed Familial HLH, Trial Finds

uncategorized

Overall five-year survival following hematopoietic stem cell transplant is higher among children with a confirmed diagnosis of familial hemophagocytic lymphohistiocytosis (HLH) than those lacking a confirmed diagnosis, a large clinical trial reported. ... Read more

September 24, 2020September 24, 2020

Only 10.4% of Suspected HLH Cases Positive for Disease-causing Mutations, Study Finds

uncategorized

Next-generation sequencing analysis for a panel of 15 genes identified disease-causing variants in only 10.4% of suspected cases of hemophagocytic lymphohistiocytosis (HLH), a new study reports. The results highlight the need ... Read more

June 18, 2020June 18, 2020

New Combo Treatment May Help Control Inflammation, Study Finds

uncategorized

Certain interleukins — proteins that can boost inflammation — promote resistance to the corticosteroid dexamethasone (DEX), a first-line treatment for hemophagocytic lymphohistiocytosis (HLH), a study shows. These proteins activate a ... Read more

March 10, 2020March 10, 2020

Pediatric Rare Disease Therapies Increase, But Most Repurposed, Study Finds

News

The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However, despite the increase, nearly 7,000 rare diseases are still lacking ... Read more

March 6, 2020March 6, 2020

1st Case of Cancer Patient Developing HLH While on Keytruda Reported

uncategorized

In a first known occurrence, a man developed hemophagocytic lymphohistiocytosis (HLH) while being treated with the immunotherapy agent Keytruda (pembrolizumab) for metastatic head and neck squamous cell carcinoma (HNSCC), a case study reported. ... Read more

January 30, 2020January 30, 2020

Despite Delay in HLH Diagnosis, Patient in Complete Remission After Chemotherapy for Lymphoma, Case Study Reports

uncategorized

Despite a five-month delay in his hemophagocytic lymphohistiocytosis (HLH) diagnosis, a 63-year-old man with lymphoma achieved complete remission after six cycles of a brentuximab-based chemotherapy, a case study reports. The ... Read more

January 2, 2020January 2, 2020

EPOCH Combo Therapy Enhances Survival for Some Patients with Non-Hodgkin’s Lymphoma-associated HLH, Phase 2 Study Shows

News

Dose-adjusted EPOCH — in combination with rituximab — shows promising results as a first-line therapy for hemophagocytic lymphohistiocytosis (HLH) in people with B-cell non-Hodgkin’s lymphoma (NHL), a Phase 2 trial ... Read more

November 21, 2019November 21, 2019

‘Cytokine Storm Syndrome’ Hopes to Educate Doctors About HLH Symptoms and Care

uncategorized

A book about hemophagocytic lymphohistiocytosis (HLH) — also known as cytokine release syndrome, macrophage activation syndrome — covers information ranging from disease symptoms and their clinical presentation to the most ... Read more

October 24, 2019November 14, 2019

Gamifant is Only Therapy Approved by FDA to Treat Primary Hemophagocytic Lymphohistiocytosis

uncategorized

Gamifant (emapalumab-lzsg) is the first therapy approved by the U.S. Food and Drug Administration for children (including newborns) and adults with primary hemophagocytic lymphohistiocytosis (HLH), who have failed to respond ... Read more